Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 5Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 4Renal Insufficiency 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Interventional × melflufen × Clear all
NCT03151811 2024-01-30

OCEAN

Oncopeptides AB

Phase 3 Terminated
495 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT04649060 2023-06-08

LIGHTHOUSE

Oncopeptides AB

Phase 3 Terminated
54 enrolled 21 charts
Plasma cell

Multiple Myeloma

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated
35 enrolled 33 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡